Moderna Inc.‘s COVID-19 vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.
A study of almost 2,500 workers at a major Belgium hospital system found antibody levels among individuals who hadn’t been infected with the coronavirus before getting two doses of the Moderna vaccine averaged 2,881 units per milliliter, compared with 1,108 units/mL in an equivalent group who got two jabs of the Pfizer shot.
For more coronavirus news, visit our dedicated page.
The results, published Monday in a letter to the Journal of the American Medical Association, suggested the differences might be explained by the: higher amount of active ingredient in the Moderna vaccine -- 100 micrograms, versus 30 micrograms in Pfizer-BioNTech, and longer interval between doses of the Moderna vaccine -- four weeks, versus three weeks for Pfizer-BioNTech.
Moderna’s vaccine was associated with a two-fold risk reduction against breakthrough SARS-CoV-2 infections compared to Pfizer’s in a review of people in the Mayo Clinic Health System in the US from January to July. The results were reported in a separate study released ahead of publication and peer review on August 9.
Read more:
Pfizer says its COVID-19 vaccine effective for children as young as 12
AstraZeneca, Pfizer vaccines proven effective against Delta COVID-19 variant: Study
Pfizer-BioNTech files for full US approval of COVID-19 vaccine
